Estradiol/drospirenone

Estradiol/drospirenone
Estradiol
Drospirenone
Combination of
EstradiolEstrogen
DrospirenoneProgestogen; Progestin; Antimineralocorticoid; Antiandrogen
Clinical data
Trade namesAngeliq
Other namesE2/DRSP; BAY-864891
Routes of
administration
By mouth
Drug classEstrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen
Legal status
Legal status
Identifiers
CAS Number

Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women. It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet. The medication was approved in the United States in 2005. It is marketed widely throughout the world.

See also